Saniona AB (STO:SANION), a research and development company focused on drugs for diseases of the central nervous system and eating disorders, announced on Monday the selection of a new development candidate, SAN903, for preclinical development, which can enter clinical phase 1 in only 18 months.
Based on work done to date, Saniona said it has elected to focus SAN903 initially on the treatment of Crohn's disease and colitis.
According to the company, SAN903, which is generated from the company's advanced ion channel platform, is a first-in-class product and, Saniona believes it has the potential to transform the treatment paradigm for severe autoimmune diseases, including Crohn's disease and colitis.
With SAN903, Saniona has identified a novel proprietary IK channel inhibitor that effectively dampens gut inflammation and can be used for the treatment of inflammatory bowel diseases (IBD), like Crohn`s disease and ulcerative colitis. The drug will likely be the first ion channel modulator for IBD.
In addition, SAN903 also has potential in certain rare blood diseases, where Saniona may obtain an orphan designation and develop the product all the way to the market.
This preclinical development of SAN903 will encompass scale-up of the manufacturing process, GMP production and various toxicology studies, which will form the basis for a regulatory application to initiate first-in-man clinical trials.
Saniona added that it is concurrently working with its development partners to initiate phase 1 clinical trials early 2021.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference